Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

Lasmiditan, a serotonin 5-HT(1F) receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled study. The current study was designed to replicate these findings in a generalizable population of patients with migraine, including those wi...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Brain
Prif Awduron: Goadsby, Peter J, Wietecha, Linda A, Dennehy, Ellen B, Kuca, Bernice, Case, Michael G, Aurora, Sheena K, Gaul, Charly
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Clinical Trial
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6620826/
https://ncbi.nlm.nih.gov/pubmed/31132795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/brain/awz134
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg